Publications by authors named "Marie-Pierre David"

Claim this Profile
I
Immune persistence and safety of the AS01-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
Murdo Ferguson, Tino F Schwarz, Sebastián A Núñez, Juan Rodríguez-García, Marek Mital, Marie-Pierre David

Hum Vaccin Immunother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and immunogenicity of the AS01-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
Michael G Ison, Alberto Papi, Eugene Athan, Robert G Feldman, Joanne M Langley, Marie-Pierre David

Lancet Respir Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial.
Rebecca Clark, Sam Davies, Jorge Labrador, Paul Loubet, Silvina Natalini Martínez, Marie-Pierre David

Clin Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.
Murdo Ferguson, Tino F Schwarz, Sebastián A Núñez, Juan Rodríguez-García, Marek Mital, Marie-Pierre David

Clin Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.
Michael G Ison, Alberto Papi, Eugene Athan, Robert G Feldman, Joanne M Langley, Marie-Pierre David

Clin Infect Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults.
Murdo Ferguson, Alexander Murray, Lew Pliamm, Lars Rombo, Johan Sanmartin Berglund, Marie-Pierre David

Vaccine X· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
Isabel Leroux-Roels, Marc Van Ranst, Corinne Vandermeulen, Carline Vanden Abeele, Nathalie De Schrevel, Marie-Pierre David

J Infect Dis· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.
Robert G Feldman, Raffaele Antonelli-Incalzi, Katie Steenackers, Dong-Gun Lee, Alberto Papi, Marie-Pierre David

Clin Infect Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains.
Lionel Sacconnay, Jonathan De Smedt, Vera Rocha-Perugini, Edison Ong, Romuald Mascolo, Marie-Pierre David

Sci Transl Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging Influenza Virus Surveillance From 2012 to 2015 to Characterize the Burden of Respiratory Syncytial Virus Disease in Canadian Adults ≥50 Years of Age Hospitalized With Acute Respiratory Illness.
May ElSherif, Melissa K Andrew, Lingyun Ye, Ardith Ambrose, Guy Boivin, Marie-Pierre David, David Richardson

Open Forum Infect Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Isabel Leroux-Roels, Matthew G Davis, Katie Steenackers, Brandon Essink, Corinne Vandermeulen, Marie-Pierre David

J Infect Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
Shady Kotb, Miwa Haranaka, Nicolas Folschweiller, Phoebe Nakanwagi, Céline Verheust, Marie-Pierre David

Respir Investig· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Alberto Papi, Michael G Ison, Joanne M Langley, Dong-Gun Lee, Isabel Leroux-Roels, Marie-Pierre David

N Engl J Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
Nicolas Folschweiller, Carline Vanden Abeele, Laurence Chu, Pierre Van Damme, Adolfo García-Sastre, Marie-Pierre David

Lancet Infect Dis· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.
Tino F Schwarz, Stephanie Volpe, Gregory Catteau, Roman Chlibek, Marie Pierre David

Hum Vaccin Immunother· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
Jiri Beran, Jason D Lickliter, Tino F Schwarz, Casey Johnson, Laurence Chu, Marie-Pierre David

J Infect Dis· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
Matti Lehtinen, Tiina Eriksson, Dan Apter, Mari Hokkanen, Kari Natunen, Marie-Pierre David

Hum Vaccin Immunother· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
Mark H Einstein, Peter Takacs, Archana Chatterjee, Rhoda S Sperling, Nahida Chakhtoura, Marie-Pierre David

Hum Vaccin Immunother· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fewer than three doses of HPV vaccine - Authors' reply.
Aimée R Kreimer, Frank Struyf, Allan Hildesheim, Marie-Pierre David, Cosette M Wheeler

Lancet Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
Aimée R Kreimer, Frank Struyf, Maria Rowena Del Rosario-Raymundo, Allan Hildesheim, S Rachel Skinner, Marie-Pierre David, David J M Lewis

Lancet Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial.
Matti Lehtinen, Dan Apter, Iacopo Baussano, Tiina Eriksson, Kari Natunen, Marie-Pierre David, David Jenkins

Vaccine· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.
Frank Struyf, Brigitte Colau, Cosette M Wheeler, Paulo Naud, Suzanne Garland, David J M Lewis, Marie-Pierre David

Clin Vaccine Immunol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.
Feng-Cai Zhu, Wen Chen, Yue-Mei Hu, Ying Hong, Juan Li, Marie-Pierre David

Int J Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
S Rachel Skinner, Anne Szarewski, Barbara Romanowski, Suzanne M Garland, Eduardo Lazcano-Ponce, Marie-Pierre David

Lancet· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine.
Maria-Genalin Angelo, Sylvia Taylor, Frank Struyf, Fernanda Tavares Da Silva, Felix Arellano, Marie-Pierre David

Expert Rev Vaccines· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis